Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Morphogen-IX

Morphogen-IX
2015 FOUNDED
PRIVATE STATUS
Series B LATEST DEAL TYPE
$11M LATEST DEAL AMOUNT
4 INVESTORS
Description

Developer of bone morphogenetic protein receptors designed to offer treatment for pulmonary arterial hypertension. The company's receptors offer therapies that alleviate the symptoms of pulmonary arterial hypertension, enabling drug discovery professionals to ensure maximum capital efficiency without sacrificing quality.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Babraham Research Campus
  • Babraham
  • Cambridge CB22 3AT
  • England, United Kingdom
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Morphogen-IX’s full profile, request a free trial.

Morphogen-IX Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series B) 18-Dec-2018 $11M 000.00 000.00 Completed Product Development
1. Early Stage VC (Series A) 18-Jan-2016 00.00 00.00 00.000 Completed Product Development
To view this company’s complete deal history including valuation and funding, request access »

Morphogen-IX Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 00,000 00.000000 00.00 00.00 00 00.00 0.00
Series B 000,000 00.000000 00.00 00.00 00 00.00 0.000
Series B 874,999 $0.012729 $10.18 $10.18 1x $10.18 24.56%
Series A 1,499,999 $0.012729 $1.27 $1.27 1x $1.27 42.1%
To view this company’s complete Cap Table, request access »

Morphogen-IX Competitors (26)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Circle Pharma Venture Capital-Backed South San Francisco, CA 0 00.00 000000000000 00.00
000000 00000000000 Formerly VC-backed Boston, MA 00 00000 00000000 00000
000000 00000000000 Failed Transaction (M&A) Cambridge, MA 000 00000 000000&0
0000000 0000000000 Venture Capital-Backed Cambridge, United Kingdom 00.00 0000000000 00.00
00000000 000000000 Venture Capital-Backed Vienna, Austria 00.000 0000000000 00.000
To view this company’s complete list of competitors, request access »

Morphogen-IX Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Medicxi Venture Capital Minority 000 0000 000000 0
Cambridge Enterprise Venture Capital Minority 000 0000 000000 0
Cambridge Innovation Capital Venture Capital Minority 000 0000 000000 0
Index Ventures Venture Capital Minority 000 0000 000000 0

Morphogen-IX Executive Team (3)

Name Title Board
Seat
Contact
Info
Nicholas Morrell MD Founder, Chief Executive Officer & Board Member
David Grainger Ph.D Board Member & Chief Scientific Officer

1 Former Executive

You’re viewing 2 of 3 executives. Get the full list »

Morphogen-IX Board Members (6)

Name Representing Role Since Contact
Info
Anne Dobree Ph.D Self Board Member 000 0000
David Grainger Ph.D Self Board Member & Chief Scientific Officer 000 0000
Kevin Johnson Ph.D Self Board Member 000 0000
Nicholas Morrell MD Morphogen-IX Founder, Chief Executive Officer & Board Member 000 0000
Robert Tansley MD Cambridge Innovation Capital Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 6 board members. Get the full list »